"You want to get on with the rest of your life": a qualitative study of health-related quality of life in gout

Priyanka Chandratre, Christian D Mallen, Edward Roddy, Jennifer Liddle, Jane Richardson, Priyanka Chandratre, Christian D Mallen, Edward Roddy, Jennifer Liddle, Jane Richardson

Abstract

The objective of the study is to examine the impact of gout and its treatments on health-related quality of life (HRQOL) using focus group interviews. From the baseline phase of a cohort study of HRQOL in gout, 17 participants (15 males, mean age 71 years) with varying attack frequency and treatment with and without allopurinol participated in one of four focus group interviews. All interviews were audio-recorded and transcribed verbatim. Data was analysed thematically. Physical and psychosocial HRQOL in gout was affected by characteristics of acute gout (particularly the unpredictable nature of attacks, location of joint involved in an attack, pain and modifications in lifestyle), lack of understanding of gout by others (association with unhealthy lifestyle, symptoms ridiculed as non-severe and non-serious) as well as participants (not considered a disease) and the lack of information provided by physicians (about causes and pharmacological as well as non-pharmacological treatments of gout). Participants emphasised the impact of acute attacks of gout and prioritised dietary modifications and treatment of acute attacks over long-term urate-lowering therapy. Characteristics of acute gout, lack of understanding and information about gout and its treatments perpetuate poor HRQOL. HRQOL (maintenance of usual diet and reduced frequency of attacks) was associated with urate-lowering treatment. Better patient, public and practitioner education about gout being a chronic condition associated with co-morbidities and poor HRQOL may improve understanding and long-term treatment of gout.

Keywords: Focus group interviews; Gout; Health-related quality of life; Primary care; Qualitative study; Thematic analysis.

Figures

Fig. 1
Fig. 1
Recruitment process for the qualitative focus group

References

    1. Kuo C, Doherty M, Grainge MJ, Zhang W. Geographic Variations Of Gout Epidemiology In The United Kingdom: A Nationwide Population Study: 1993[Abstract] Arthritis Rheum. 2013;65(Supplement 10):S850.
    1. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, So AK, Bardin T (2012) Gout: why is this curable disease so seldom cured? Ann Rheum Dis 71(11):1765–70
    1. Choi HK, Ford ES, Li C, Curhan G. Prevalence of the metabolic syndrome in patients with gout: The Third National Health and Nutrition Examination Survey. Arthritis Care Res. 2007;57(1):109–15. doi: 10.1002/art.22466.
    1. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control study. Rheumatology. 2007;46(9):1441–4. doi: 10.1093/rheumatology/kem150.
    1. Hayward RA, Rathod T, Roddy E, Muller S, Hider SL, Mallen CD. The association of gout with socioeconomic status in primary care: a cross-sectional observational study. Rheumatology. 2013;52(11):2004–8. doi: 10.1093/rheumatology/ket262.
    1. Taylor W, Smeets L, Hall J, McPherson K. The burden of rheumatic disorders in general practice: consultation rates for rheumatic disease and the relationship to age, ethnicity, and small-area deprivation. N Z Med J. 2004;117(1203):U1098.
    1. Patrick DL, Erickson P. Health status and health policy: quality of life in health care evaluation and resource allocation. Oxford: Oxford University Press; 1993.
    1. Singh JA. The impact of gout on patient's lives: a study of African-American and Caucasian men and women with gout. Arthritis Res Ther. 2014;16(3):R132. doi: 10.1186/ar4589.
    1. Harrold LR, Mazor KM, Velten S, Ockene IS, Yood RA. Patients and providers view gout differently: a qualitative study. Chronic Illness. 2010;6(4):263–71. doi: 10.1177/1742395310378761.
    1. Lindsay K, Gow P, Vanderpyl J, Logo P, Dalbeth N. The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach. J Clin Rheumatol. 2011;17(1):1–6. doi: 10.1097/RHU.0b013e318204a8f9.
    1. Harrold LR, Mazor KM, Peterson D, Firneno C, Yood RA. Patient knowledge and beliefs concerning gout and its treatment. Arthritis Rheum. 2010;62
    1. Spencer K, Carr A, Doherty M. Patient and provider barriers to effective management of gout in general practice: a qualitative study. Ann Rheum Dis. 2012;71(9):1490–5. doi: 10.1136/annrheumdis-2011-200801.
    1. Singh JA. Challenges faced by patients in gout treatment: a qualitative study. J Clin Rheumatol. 2014;20(3):172–4. doi: 10.1097/RHU.0000000000000091.
    1. Chandratre P, Mallen C, Richardson J, Rome K, Bailey J, Gill R, Hider S, Mason J, Mayson Z, Muller S, Purcell C, Titley J, Wathall S, Zwierska I, Roddy E (2012) Prospective observational cohort study of Health Related Quality of Life (HRQOL), chronic foot problems and their determinants in gout: a research protocol. BMC Musculoskelet Disord 13(1):219
    1. Barbour R. Doing focus groups. Sage Publications Limited; 2008
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101. doi: 10.1191/1478088706qp063oa.
    1. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, Harvey J, Kavanaugh A (2008) Evaluation of an instrument assessing influence of gout on health-related quality of life. J Rheumatol 35(12):2406–14
    1. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, Joseph-Ridge N (2007) The impact of gout on work absence and productivity. Value Health 10(4):231–7
    1. Chandratre P, Roddy E, Mallen C. Patient related factors are also important in treating gout. BMJ. 2012;344:e191. doi: 10.1136/bmj.e191.
    1. Khanna PP, Perez-Ruiz F, Maranian P, Khanna D. Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short form-36 is responsive to change in chronic gout. Rheumatology. 2011;50(4):740–745. doi: 10.1093/rheumatology/keq346.
    1. Kuo C, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Annals of the Rheumatic Diseases. 2014 January 15
    1. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310–6. doi: 10.1136/ard.2007.081604.
    1. Becker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J. Quality of life and disability in patients with treatment-failure gout. J Rheumatol. 2009;36(5):1041–8. doi: 10.3899/jrheum.071229.
    1. Eisenberg L. Disease and illness distinctions between professional and popular ideas of sickness. Cult Med Psychiatry. 1977;1(1):9–23. doi: 10.1007/BF00114808.
    1. Conrad P, Barker KK. The social construction of illness: key insights and policy implications. J Health Soc Behav. 2010;51(1 suppl):S67–79. doi: 10.1177/0022146510383495.
    1. Lee SJ, Hirsch JD, Terkeltaub R, Khanna D, Singh JA, Sarkin A, Kavanaugh A (2009) Perceptions of disease and health-related quality of life among patients with gout. Rheumatology 48(5):582–6
    1. Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: results from a cross-sectional survey. Health Qual Life Outcomes 10:117
    1. Roddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther. 2010;12:223. doi: 10.1186/ar3199.
    1. Alvarez-Nemegyei J, Cen-Piste JC, Medina-Escobedo M, Villanueva-Jorge S. Factors associated with musculoskeletal disability and chronic renal failure in clinically diagnosed primary gout. J Rheumatol. 2005;32(10):1923–7.
    1. Dalbeth N, Petrie KJ, House M, Chong J, Leung W, Chegudi R, Horne A, Gamble G, McQueen FM, Taylor WJ (2011) Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability. Arthritis Care Res 63(11):1605–12
    1. Bowling A. Research methods in health. Open University Press Maidenhead; 2009
    1. Spencer KT, Carr A, Doherty M. Patient-related barriers to the effective management and treatment of gout. Rheumatology.Conference: Rheumatology 2011 Brighton United Kingdom.Conference Start: 20110412 Conference End: 20110414.Conference Publication: (var.pagings). 2011 April 2011;50:84-5.
    1. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology. 2009;48 Suppl 2:ii9–ii14.
    1. Roddy E, Mallen CD, Doherty M. BMJ. 2013 BMJ Publishing Group Ltd;347.
    1. Edwards NL. Treatment-failure gout: a moving target. Arthritis Rheum. 2008;58(9):2587–90. doi: 10.1002/art.23803.
    1. Gaffo AL, Edwards NL, Saag KG. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link? Arthritis Res Ther. 2009;11(4):240. doi: 10.1186/ar2761.
    1. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, EUROSPAN Consortium, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, ENGAGE Consortium, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J et al (2009) Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS genetics 5(6):e1000504

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere